{"entity":{"id":"nct06222489","kind":"trial","name":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","aka":[],"tldr":"A phase 2 trial in lung cancer, run by The Netherlands Cancer Institute, now recruiting.","summary":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT is a phase 2, interventional study registered as NCT06222489 by The Netherlands Cancer Institute, with a registry enrolment figure of 16 participants, started 2025-03-03 and due to reach its primary completion in 2027-05-01. Interventions recorded: 89Zr-Patritumab deruxtecan. Conditions listed: Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer; EGFR Gene Mutation. Primary outcome: The optimal imaging dose patritumab deruxtecan to co-inject with 89Zr-Patritumab deruxtecan (HER3-DXd), defined by adequate visualisation of the circulation five days after tracer injection.. Lung eligibility wording from the registry: \"Have a histologically or cytologically confirmed diagnosis of (locally) advanced stage EGFR mutation positive NSCLC, not amenable for curative intent treatment\". Sites: Netherlands. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06222489","url":"https://clinicaltrials.gov/study/NCT06222489"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06222489","phase":"2","setting":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","sponsor":"The Netherlands Cancer Institute","enrolled":16,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06222489/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}